行情

PTCT

PTCT

PTC Therapeutics
NASDAQ

实时行情|Nasdaq Last Sale

48.25
+0.53
+1.11%
盘后: 48.25 0 0.00% 17:00 12/13 EST
开盘
47.39
昨收
47.72
最高
48.75
最低
47.20
成交量
98.05万
成交额
--
52周最高
50.96
52周最低
27.53
市值
29.74亿
市盈率(TTM)
-11.8828
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PTCT 新闻

  • PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • PR Newswire.1小时前
  • The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend
  • Benzinga.12/06 12:39
  • Stocks That Hit 52-Week Highs On Thursday
  • Benzinga.12/05 15:16
  • Hedge Funds Have Never Been This Bullish On PTC Therapeutics, Inc. (PTCT)
  • Insider Monkey.12/05 03:23

更多

所属板块

生物技术和医学研究
-0.88%
制药与医学研究
-0.08%

热门股票

名称
价格
涨跌幅

PTCT 简况

PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.
展开

Webull提供PTC Therapeutics, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。